Cargando…
Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450219/ https://www.ncbi.nlm.nih.gov/pubmed/36091381 http://dx.doi.org/10.3389/fphys.2022.1020568 |
| _version_ | 1784784477849911296 |
|---|---|
| author | Frontiers Editorial Office, |
| author_facet | Frontiers Editorial Office, |
| author_sort | Frontiers Editorial Office, |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9450219 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94502192022-09-08 Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway Frontiers Editorial Office, Front Physiol Physiology Frontiers Media S.A. 2022-08-24 /pmc/articles/PMC9450219/ /pubmed/36091381 http://dx.doi.org/10.3389/fphys.2022.1020568 Text en Copyright © 2022 Frontiers Editorial Office. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Physiology Frontiers Editorial Office, Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway |
| title | Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway |
| title_full | Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway |
| title_fullStr | Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway |
| title_full_unstemmed | Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway |
| title_short | Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway |
| title_sort | retraction: mir-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/pgc-1α pathway |
| topic | Physiology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450219/ https://www.ncbi.nlm.nih.gov/pubmed/36091381 http://dx.doi.org/10.3389/fphys.2022.1020568 |
| work_keys_str_mv | AT frontierseditorialoffice retractionmir22inhibitionalleviatescardiacdysfunctionindoxorubicininducedcardiomyopathybytargetingthesirt1pgc1apathway |